Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature

• Published in: International journal of molecular sciences 2024-02, Vol.25 (3), p.1909
• Main Authors: Pavli, Polina, Triantafyllidou, Olga, Kapantais, Efthymios, Vlahos, Nikolaos F, Valsamakis, Georgios
• Format: Article
• Language: English
• Subjects: Body mass index; Chronic diseases; Diabetes therapy; Dietary restrictions; Embryonic development; Estrogens; Female; Females; Fertility; fertility improvement; GLP-1 RA; GLP-1 receptor agonists; Glucagon-Like Peptide 1; Humans; Hypoglycemic agents; Infertility; Infertility, Female - therapy; Lifestyles; Male; medically induced weight loss; Menstruation; Obesity; obesity and fertility outcomes; Overweight; Ovulation; Plasma; Polycystic ovary syndrome; Pregnancy; Reproduction; Reproductive organs; Roflumilast; Sexual disorders; Sibutramine; Sperm Motility; Testosterone; Weight control; Weight Loss; Women; Womens health
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25031909

Infertility is a modern health problem. Obesity is another expanding health issue associated with chronic diseases among which infertility is also included. This review will focus on the effects of weight loss by medical therapy on fertility regarding reproductive hormonal profile, ovulation rates, time to pregnancy, implantation rates, pregnancy rates, normal embryo development, and live birth rates. We comprised medicine already used for weight loss, such as orlistat and metformin, and emerging medical treatments, such as Glucagon-Like Peptide-1 receptor agonists (GLP-1 RA). Their use is not recommended during a planned pregnancy, and they should be discontinued in such cases. The main outcomes of this literature review are the following: modest weight loss after medication and the duration of the treatment are important factors for fertility improvement. The fecundity outcomes upon which medical-induced weight loss provides significant results are the female reproductive hormonal profile, menstrual cyclicity, ovulation and conception rates, and pregnancy rates. Regarding the male reproductive system, the fertility outcomes that feature significant alterations after medically induced weight loss are as follows: the male reproductive hormonal profile, sperm motility, movement and morphology, weight of reproductive organs, and sexual function. The newer promising GLP-1 RAs show expectations regarding fertility improvement, as they have evidenced encouraging effects on improving ovulation rates and regulating the menstrual cycle. However, more human studies are needed to confirm this. Future research should aim to provide answers about whether medical weight loss therapies affect fertility indirectly through weight loss or by a possible direct action on the reproductive system.